• Tianmi Yang, Yi Xiao, Yangfan Cheng, Jingxuan Huang, Qianqian Wei, Chunyu Li, and Huifang Shang.
• Department of Neurology, Sichuan University, Chengdu, Sichuan, China.
• J. Neurol. Neurosurg. Psychiatr. 2023 Dec 1; 94 (12): 106410701064-1070.

BackgroundBiological ageing is one of the principal risk factors for neurodegenerative diseases. It is becoming increasingly clear that acceleration of DNA methylation age, as measured by the epigenetic clock, is closely associated with many age-related diseases.MethodsWe searched the PubMed and Web of Science databases to identify eligible studies reporting epigenetic clocks in several neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD).ResultsTwenty-three studies (12 for AD, 4 for PD, 5 for ALS, and 2 for HD) were included. We systematically summarised the clinical utility of 11 epigenetic clocks (based on blood and brain tissues) in assessing the risk factors, age of onset, diagnosis, progression, prognosis and pathology of AD, PD, ALS and HD. We also critically described our current understandings to these evidences, and further discussed key challenges, potential mechanisms and future perspectives of epigenetic ageing in neurodegenerative diseases.ConclusionsEpigenetic clocks hold great potential in neurodegenerative diseases. Further research is encouraged to evaluate the clinical utility and promote the application.Prospero Registration NumberCRD42022365233.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

20 keywords...

hide…